SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:liu-134507"
 

Sökning: onr:"swepub:oai:DiVA.org:liu-134507" > High Dose beta-Bloc...

High Dose beta-Blocker Therapy Triggers Additional Reverse Remodeling in Patients With Idiopathic Non-Ischemic Cardiomyopathy A Lesson From a Preliminary Trial Including the Significance of Left Ventricular Diameter and BNP Change for Reverse Remodeling

Nitta, Daisuke (författare)
University of Tokyo, Japan
Kinugawa, Koichiro (författare)
Toyama University, Japan
Imamura, Teruhiko (författare)
University of Tokyo, Japan
visa fler...
Perkiö Kato, Naoko (författare)
Linköpings universitet,Medicinska fakulteten,Avdelningen för omvårdnad,University of Tokyo, Japan
Komuro, Issei (författare)
University of Tokyo, Japan
visa färre...
 (creator_code:org_t)
INT HEART JOURNAL ASSOC, 2016
2016
Engelska.
Ingår i: International Heart Journal. - : INT HEART JOURNAL ASSOC. - 1349-2365 .- 1349-3299. ; 57:6, s. 717-724
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Carvedilol has established its evidence to improve prognosis and facilitate left ventricular reverse remodeling (LVRR) in heart failure patients with reduced left ventricular ejection fraction (LVEF), and many studies have supported its dose-dependency. However, there are few studies demonstrating the effect of high dose carvedilol in Japan. We enrolled 23 patients with idiopathic non-ischemic cardiomyopathy, in whom LVEF remained 45% or less despite 20 mg/ day of carvedilol therapy for amp;gt; 3 months. After high dose (40 mg/day) carvedilol therapy for amp;gt; 3 months, LVEF improved (+9.1%, P = 0.002), and LV end-diastolic diameter (LVDd) and LV end-systolic diameter (LVDs) reduced (-4.6 and -6.9 mm, respectively, P amp;lt; 0.05) compared with the baseline data. Finally, 17 patients achieved LVRR after the high dose, when LVRR was defined as 1) those with final EF amp;gt; 45%, and 2) those with final EF amp;lt; 45% but who attained increases in LVEF amp;gt; 10%, or LVEF amp;gt; 5% with a decrease in LV end-diastolic dimension index (LVDDI) amp;gt; 5%. Baseline predictors for LVRR after high dose carvedilol were the change rates of log B-type natriuretic peptide (BNP), LVDd, and LVDs from the time of pre-carvedilol introduction to enrollment (P amp;lt; 0.05, respectively). In conclusion, high dose carvedilol triggered additional LVRR in patients with idiopathic non-ischemic cardiomyopathy and the change rates of log BNP, LVDd, and LVDs at 20 mg carvedilol may be predictors for the additional LVRR at high dose.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Nyckelord

Carvedilol; Heart failure; Ejection fraction

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy